patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug · small molecule

save

CLARISCAN

Marketedupdated 2mo ago

by $HCA HCA Healthcare, Inc.🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval, with 1 investigational indication.

all catalysts(7)

approval · 7

News(0)

no news has mentioned this drug yet

brand

CLARISCAN

trade names

Dotarem

generic

GADOTERATE MEGLUMINE

MOA

12.1 Mechanism of Action Gadoterate is a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. The magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occurs with: 1) differences in proton density 2) differences of the spin-lattice or longitudinal relaxation times (T1) 3) differences in the spin-spin or transverse relaxation time (T2) When placed in a magnetic field, gadoterate shortens the T1 and T2 relaxation times in target tissues. At recommended doses, the effect is observed with greatest sensitivity in the T1-weighted sequences.

phase

marketed

CLARISCAN

all catalysts(7)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside

Trials studying CLARISCAN